Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial -

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
Information type: Other primary research
Source: The Lancet Haematology
Specialities: Cancers | Haematological disorders
Summary
This single arm study (n=31) in patients with rituxumab refractory disease found a 90% overall response rate with ibrutinib. The18 month progression free survival and overall survival were 86% and 97% respectively.
UKMi comment
A related commentary details that the results of this study are promising, and that chemotherapy free treatment for patients with Waldenstrom’s macroglobulinaemia may be possible. Additional issues need to be considered however, including the high cost of ibrutinib treatment, with the financial burden being compounded by the fact that ibrutinib requires indefinite administration.
Related links: Commentary